Earlier this year we got in touch with Dr David Edwards, Preclinical Scientist, Cancer Research UK, to talk about the industry ahead of his talk at the World Immunotherapy congress taking place this November.
1. What do you think has been the biggest achievement within the immunotherapy sector in the last 12 months?
The emerging clinical data showing that anti-CTLA4/anti-PD1 therapy combinations have an additive benefit which hopefully will continue to drive development of other immune checkpoint agonists and antagonists into the clinic so that other novel combinations can be explored to examine their clinical utility.
2. What important points do you hope to convey at the congress, and what information can you give me now that delegates can look forward to?
I hope to present my audience with a flavour of the types of biologics that we translate into clinical trials at the Centre for Drug Development and our approach to doing so efficiently whilst adhering to the principles of the 3R’s.
3. What do you think will be the biggest topic of discussion at this November’s World Immunotherapy Congress?
Without doubt the growth in the field of CAR T-cell technologies will be a big topic of discussion at the conference.
4. What are you looking forward to the most at the World Immunotherapy congress?
I am looking forward to listening to the session on oncolytic virus development; I’d like to understand how experts in the area plan to move more of these agents from exploratory clinical trials and into late stage trials.
5. What do you think will be the take home messages from the congress?
The congress will no doubt reinforce the message that research in immunotherapy will have an enormous impact on cancer drug development over the next few years.
To find out who else will be speaking at the World Immunotherapy Congress 2016 download the brochure.